Emergent Biosolutions Valuation
| EBS Stock | USD 5.72 0.01 0.17% |
At this time, the firm appears to be overvalued. Emergent Biosolutions shows a prevailing Real Value of $5.49 per share. The current price of the firm is $5.72. Our model computes the value of Emergent Biosolutions from reviewing the firm fundamentals such as Shares Outstanding of 54.18 M, profit margin of (0.19) %, and Current Valuation of 875.01 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Emergent Biosolutions' valuation include:
Price Book 0.6438 | Enterprise Value | Enterprise Value Ebitda 23.7129 | Price Sales 0.2978 | Forward PE 17.8891 |
Overvalued
Today
Please note that Emergent Biosolutions' price fluctuation is relatively risky at this time. Calculation of the real value of Emergent Biosolutions is based on 3 months time horizon. Increasing Emergent Biosolutions' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Emergent stock is determined by what a typical buyer is willing to pay for full or partial control of Emergent Biosolutions. Since Emergent Biosolutions is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Emergent Stock. However, Emergent Biosolutions' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.72 | Real 5.49 | Target 12.0 | Hype 5.72 | Naive 6.31 |
The intrinsic value of Emergent Biosolutions' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Emergent Biosolutions' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Emergent Biosolutions helps investors to forecast how Emergent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Emergent Biosolutions more accurately as focusing exclusively on Emergent Biosolutions' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Emergent Biosolutions' intrinsic value based on its ongoing forecasts of Emergent Biosolutions' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Emergent Biosolutions' closest peers.
Emergent Biosolutions Cash |
|
Emergent Valuation Trend
Emergent Biosolutions' real value is important for investors to make better decisions and a more accurate overall view of Emergent Biosolutions' financial worth over time. Using both Emergent Biosolutions' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Emergent Revenue by Product
Emergent Biosolutions Total Value Analysis
Emergent Biosolutions is currently forecasted to have company total value of 875.01 M with market capitalization of 540.22 M, debt of 663.7 M, and cash on hands of 642.6 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Emergent Biosolutions fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
875.01 M | 540.22 M | 663.7 M | 642.6 M |
Emergent Biosolutions Investor Information
About 58.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.64. Some equities with similar Price to Book (P/B) outperform the market in the long run. Emergent Biosolutions has Price/Earnings To Growth (PEG) ratio of 1.55. The entity recorded a loss per share of 11.22. The firm had not issued any dividends in recent years. Based on the key indicators related to Emergent Biosolutions' liquidity, profitability, solvency, and operating efficiency, Emergent Biosolutions is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Emergent Biosolutions Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Emergent Biosolutions has an asset utilization ratio of 72.94 percent. This implies that the Company is making $0.73 for each dollar of assets. An increasing asset utilization means that Emergent Biosolutions is more efficient with each dollar of assets it utilizes for everyday operations.Emergent Biosolutions Ownership Allocation
Emergent Biosolutions holds a total of 54.18 Million outstanding shares. Over half of Emergent Biosolutions' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that on January 13, 2025, Representative Steve Cohen of US Congress acquired under $15k worth of Emergent Biosolutions's common stock.Emergent Biosolutions Profitability Analysis
The company reported the last year's revenue of 1.01 B. Reported Net Loss for the year was (190.6 M) with profit before taxes, overhead, and interest of 290.1 M.About Emergent Biosolutions Valuation
The stock valuation mechanism determines Emergent Biosolutions' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Emergent Biosolutions based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Emergent Biosolutions. We calculate exposure to Emergent Biosolutions's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Emergent Biosolutions's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1 B | 1.1 B | |
| Pretax Profit Margin | (0.14) | (0.13) | |
| Operating Profit Margin | (0.11) | (0.10) | |
| Net Loss | (0.19) | (0.18) | |
| Gross Profit Margin | 1.00 | 1.05 |
Emergent Biosolutions Growth Indicators
Investing in growth stocks can be very risky. If the company such as Emergent Biosolutions does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 53 M | |
| Quarterly Earnings Growth Y O Y | 0.022 | |
| Forward Price Earnings | 17.8891 |
Emergent Biosolutions Current Valuation Indicators
Emergent Biosolutions' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Emergent Biosolutions' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Emergent Biosolutions, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Emergent Biosolutions' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Emergent Biosolutions' worth.Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.